YIFANG in Action to Combat COVID-19

2021.03.29

YIFANG Pharmaceutical Approval to Achieve the "pneumonia No.1" Production within 72-hour Breakthrough of COVID-19

 
YIFANG in Action to Combat COVID-19

Guangdong YIFANG Pharmaceutical receive the united Arab emirates (hereinafter referred to as the united Arab emirates) department of health and prevention (MOH) approved the drug registration approval documents issued by the approval of YIFANG pharmaceutical production plant medicine emergency change wet disease and particles is in line with the united Arab emirates registered product standard, marks the formal wet disease and particles in the drug identification to enter the united Arab emirates markets.

In the united Arab emirates, wet disease and high-level particles got the royal family and the local government and the recognition of the competent department of health, specially invited Chinese developers hold seminars, insight into the principle, clinical curative effect of wet disease and particle characteristics and drug safety, the experimental results, approval will become wet disease and eventually the united Arab emirates particles as a registered emergency medicine.